PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials.

ABSTRACT:

Introduction

Atherosclerosis is the leading cause of cardiovascular disease (CVD), which is one of the most common causes of morbidity and mortality worldwide. Lipid accumulation and inflammation play a crucial role in the pathogenesis of atherosclerosis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an emerging lipid-lowering agent reported as a potential anti-inflammation effect in the prevention of CVD. However, the anti-inflammatory effect is still elusive. Therefore, a systematic review and meta-analysis is needed to analyse the anti-inflammatory effect of PCSK9 inhibitors on atherosclerosis in practice.

Methods and analysis

This protocol was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. We w

SUBMITTER: Luo J 

PROVIDER: S-EPMC9693878 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature